Equities research analysts at Guggenheim assumed coverage on shares of Foamix Pharmaceuticals (NASDAQ:FOMX) in a research note issued on Tuesday, The Fly reports. The firm set a “buy” rating on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently commented on FOMX. HC Wainwright started coverage on Foamix Pharmaceuticals in a research report on Thursday, August 24th. They set a “buy” rating and a $12.00 price target on the stock. Zacks Investment Research cut Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.

Shares of Foamix Pharmaceuticals (NASDAQ:FOMX) traded down $0.02 during trading hours on Tuesday, reaching $5.59. The company’s stock had a trading volume of 91,570 shares, compared to its average volume of 159,808. Foamix Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $11.27.

Foamix Pharmaceuticals (NASDAQ:FOMX) last announced its quarterly earnings data on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.47) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.03). Foamix Pharmaceuticals had a negative net margin of 1,439.32% and a negative return on equity of 54.81%. The business had revenue of $0.90 million during the quarter, compared to the consensus estimate of $0.90 million. During the same quarter last year, the company earned ($0.19) EPS. The firm’s revenue for the quarter was down 64.6% compared to the same quarter last year. equities research analysts expect that Foamix Pharmaceuticals will post -1.34 earnings per share for the current fiscal year.

Several hedge funds and other institutional investors have recently modified their holdings of FOMX. Marshall Wace North America L.P. lifted its position in shares of Foamix Pharmaceuticals by 42.7% during the 2nd quarter. Marshall Wace North America L.P. now owns 632,819 shares of the specialty pharmaceutical company’s stock valued at $3,164,000 after buying an additional 189,350 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Foamix Pharmaceuticals by 38.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 544,853 shares of the specialty pharmaceutical company’s stock valued at $2,528,000 after buying an additional 151,849 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Foamix Pharmaceuticals by 363.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 148,981 shares of the specialty pharmaceutical company’s stock valued at $737,000 after buying an additional 116,861 shares during the last quarter. AXA lifted its position in shares of Foamix Pharmaceuticals by 14.1% during the 2nd quarter. AXA now owns 942,735 shares of the specialty pharmaceutical company’s stock valued at $4,374,000 after buying an additional 116,298 shares during the last quarter. Finally, PDT Partners LLC purchased a new position in shares of Foamix Pharmaceuticals during the 2nd quarter valued at $304,000. 57.43% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Guggenheim Initiates Coverage on Foamix Pharmaceuticals (FOMX)” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this piece on another site, it was illegally copied and republished in violation of United States and international copyright & trademark law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/05/guggenheim-initiates-coverage-on-foamix-pharmaceuticals-fomx.html.

About Foamix Pharmaceuticals

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

The Fly

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.